Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
The Quality-of-Life Balance: Anticholinergics in the Hot Seat
12 December 2003. A case report in the December 5 issue of the New England Journal of Medicine presents an example of the potential dangers of anticholinergic drugs in some patients: short-term memory loss and hallucinations.

Anecdotally, many specialists are aware that drugs with anticholinergic properties can cause neuropsychological deficits. There is even evidence from a study by Elaine Perry and colleagues (Perry et al., 2003) that these drugs—including common drugs for incontinence, hypertension, psychosis, mood disorders, even allergies—might contribute to the pathology of Alzheimer's disease (see ARF related news story). Still, physicians have to help their patients balance quality-of-life issues, and for many people, these drugs are of great benefit.

Treating incontinence can clearly raise the quality of life for some elderly, but at what price? In their case report, Jack Tsao of the Naval Hospital in Jacksonville, Florida, and Kenneth Heilman of the Veterans Affairs Medical Center in Gainesville, Florida, describe a 73-year-old woman who experienced hallucinations and short-term memory loss when she first started taking the incontinence drug tolterodine. Her primary care physician suspected dementia and prescribed the cholinesterase inhibitor donepezil, which improved the memory problems. (The hallucinations also stopped, though the woman so enjoyed the conversations with deceased relatives that she initially hadn't reported them.) When the patient stopped taking tolterodine for several months, her memory improved further. When she began taking the drug again, there was another drop in short-term memory. With a second discontinuation, memory performance again rose, though not immediately.

"The half-life of tolterodine is less than 10 hours, but in this case, memory normalized long after its use was discontinued, suggesting that the medication altered gene regulation or protein expression," write the authors. Citing, among other things, the work of Perry and colleagues, the authors conclude with recommendations for judicious use of anticholinergics in older patients, along with memory testing of these patients.—Hakon Heimer.

Reference:
Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med. 2003 Dec 4;349(23):2274-5. No abstract available. Abstract

 
Comments on News and Primary Papers
  Comment by:  John Morris, ARF Advisor (Disclosure)
Submitted 12 December 2003  |  Permalink Posted 12 December 2003

The Case Report by Drs. Tsao and Heilman calls needed attention to a syndrome, often mimicking that of a dementing illness, of potentially reversible cognitive dysfunction associated with anticholinergic drugs used for the treatment of common bladder disturbances in older adults. Experience suggests that this syndrome is under-recognized, particularly by those physicians who are most likely to prescribe anticholinergic drugs for bladder dysfunction. Tsao and Heilman properly recommend judicious use of such medications in elderly patients who may be at risk for cognitive impairment. The problem is that, in some individuals, the drugs have real benefit for incontinence syndromes with corresponding improvement in quality of life.

Many questions need to be resolved before we will understand the appropriate role of these drugs in clinical practice. How prevalent is the syndrome of anticholinergic-associated cognitive dysfunction in older adults? Are some patients more susceptible than others, and if so, how might they be screened prior to initiation of treatment? Are certain...  Read more


  Comment by:  georges Otte
Submitted 14 December 2003  |  Permalink Posted 16 December 2003

As cholinergic M1 receptor blockage will inhibit the production of NGF and possibly decrease sAPPalfa formation one should be aware that prolonged anticholinergic treatment could enhance the neurdegeneration of cholinergic neurons in the Meynert nucleus and therefore augment the already deleterious effect of the oligomeric abeta42 ligands at the synapse. Clinicians should take care to avoid these "iatrogenic" pitfalls. Lessons from recent cell biological insights should be translated into good clinical practice.

View all comments by georges Otte

  Comment by:  Gladys Brown
Submitted 15 December 2003  |  Permalink Posted 16 December 2003

This was a useful article for me because my sleep is often disrupted because of my need to urinate. There have also been times when I have thought that I was becoming incontinent. With this information I will be much more assiduous about strengthening my muscles and reducing my caregiver stress which may be contributing to my difficulties before I take any medication.

View all comments by Gladys Brown

  Comment by:  Thomas Beach
Submitted 1 March 2004  |  Permalink Posted 1 March 2004

The NEJM article is good for reminding us that blocking muscarinic receptors may impair cognition and alter perception in anyone, but especially in the elderly. As loss of cortical cholinergic afferents is a normal aging change in humans, the elderly are normally in a state of cholinergic deprivation and therefore are more sensitive to further losses in cholinergic transmission. Those who are harboring advanced AD pathology are probably even more susceptible.

View all comments by Thomas Beach
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad